Client News

Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

Adocia announces its financial calendar for 2020

Lindis Blood Care GmbH: Over 5 million euros for Lindis Blood Care – development of a new product for the removal of tumor cells from surgical blood

SYNIMMUNE GmbH Reports Interim Results of First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia

Motif Bio plc: Confirmation of timing of voluntary delisting from the NASDAQ Capital Market

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

Bencard Allergie GmbH: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme

MagForce AG:New hope for brain tumor patients in Saxony: Paracelsus Clinic Zwickau and MagForce AG open new NanoTherm therapy center for the East German region